Compass Therapeutics, Inc. (CMPX)

Market Cap	428.68M
Revenue (ttm)	n/a
Net Income (ttm)	-62.03M
Shares Out	138.28M
EPS (ttm)	-0.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,366,762
Open	3.110
Previous Close	3.170
Day's Range	3.010 - 3.305
52-Week Range	1.140 - 4.080
Beta	1.30
Analysts	Strong Buy
Price Target	13.50 (+335.48%)
Earnings Date	Aug 11, 2025

About CMPX

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 35
• Stock Exchange: NASDAQ
• Ticker Symbol: CMPX
• Website: https://www.compasstherapeutics.com

Analyst Forecast

According to 8 analysts, the average rating for CMPX stock is "Strong Buy." The 12-month stock price target is $13.5, which is an increase of 335.48% from the latest price.

Price Target

$13.5

(335.48% upside)

Analyst Consensus: Strong Buy